China Universal Asset Management Company’s ArriVent BioPharma AVBP Stock Holding History

China Universal Asset Management Company’s Portfolio AVBP Stock Details AVBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$257K	Buy	7,412 +86	+1%	+$2.54K	0.02%	335
2026 Q1	$169K	Buy	7,326 +599	+9%	+$13.5K	0.01%	364
2025 Q4	$135K	Sell	6,727 -384	-5%	-$7.99K	0.01%	385
2025 Q3	$131K	Buy	7,111 +240	+3%	+$4.71K	0.01%	366
2025 Q2	$150K	Buy	6,871 +112	+2%	+$2.33K	0.01%	335
2025 Q1	$125K	Sell	6,759 -386	-5%	-$9.45K	0.01%	346
2024 Q4	$190K	Buy	+7,145	New	+$205K	0.02%	329

Other funds holding AVBP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return

Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

MAP

Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Ellsworth Advisors Hudson, Ohio $609M AUM 52.37% 1-Year Est. Return

China Universal Asset Management Company's AVBP Position: Q2 2026 in Review

China Universal Asset Management Company increased its ArriVent BioPharma (AVBP) stake by 1.2% in Q2 2026, buying an estimated $2.54K and bringing the position to 7,412 shares worth $257K. The position accounts for 0.02% of the portfolio, ranked #335.

China Universal Asset Management Company first reported a position in AVBP in Q4 2024 and has held it in 7 quarters since. 40 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

China Universal Asset Management Company held 7,412 shares of ArriVent BioPharma worth $257K as of Q2 2026.
China Universal Asset Management Company bought 86 ArriVent BioPharma shares in Q2 2026, an estimated $2.54K.
ArriVent BioPharma made up 0.02% of China Universal Asset Management Company's portfolio in Q2 2026, its #335 holding.
China Universal Asset Management Company first reported a position in ArriVent BioPharma in Q4 2024 and has held it in 7 quarters since.
40 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.